Aim: To investigate an "optimal" therapeutic management of patients with papillary thyroid microcarcinoma (PTMC). Methods: We evaluated a group of 403 consecutive patients affected by PTMC operated on by the same surgeon. Prognostic factors were evaluated by uni- and multivariate statistical analysis. Results: After a mean follow-up of 8.5 years, 372 patients were living without disease (undetectable serum thyroglobulin levels), 24 patients were living with disease (increased serum thyroglobulin levels), 6 patients were deceased due to causes different from thyroid cancer, and 1 patient was deceased due to metastatic thyroid cancer. No statistically significant prognostic factor was found at uni- and multivariate analysis. However, it is worth noting that in patients with a larger primary tumour (size ≥ 5 mm) and treated by partial thyroidectomy alone, the prevalence of recurrent disease was higher than in patients treated by total thyroidectomy and 131I administration. Conclusion: It appears reasonable to perform total thyroidectomy (possibly associated with central compartment node dissection), 131I whole body scan (followed by 131I therapy when necessary) and TSH-suppressive hormonal therapy in patients with PTMC. © 2006 Elsevier Ltd. All rights reserved.
Pelizzo M.R., Boschin I.M., Toniato A., Piotto A., Bernante P., Pagetta C., et al. (2006). Papillary thyroid microcarcinoma (PTMC): Prognostic factors, management and outcome in 403 patients. EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 32(10), 1144-1148 [10.1016/j.ejso.2006.07.001].
Papillary thyroid microcarcinoma (PTMC): Prognostic factors, management and outcome in 403 patients
Bernante P.;
2006
Abstract
Aim: To investigate an "optimal" therapeutic management of patients with papillary thyroid microcarcinoma (PTMC). Methods: We evaluated a group of 403 consecutive patients affected by PTMC operated on by the same surgeon. Prognostic factors were evaluated by uni- and multivariate statistical analysis. Results: After a mean follow-up of 8.5 years, 372 patients were living without disease (undetectable serum thyroglobulin levels), 24 patients were living with disease (increased serum thyroglobulin levels), 6 patients were deceased due to causes different from thyroid cancer, and 1 patient was deceased due to metastatic thyroid cancer. No statistically significant prognostic factor was found at uni- and multivariate analysis. However, it is worth noting that in patients with a larger primary tumour (size ≥ 5 mm) and treated by partial thyroidectomy alone, the prevalence of recurrent disease was higher than in patients treated by total thyroidectomy and 131I administration. Conclusion: It appears reasonable to perform total thyroidectomy (possibly associated with central compartment node dissection), 131I whole body scan (followed by 131I therapy when necessary) and TSH-suppressive hormonal therapy in patients with PTMC. © 2006 Elsevier Ltd. All rights reserved.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.